A Phase 2 interventional study of LY4086940 and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Not yet recruiting at 46 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.
Participation in the study will last about 58 weeks.
6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.
This study's planned enrollment of 460 is above the median of 77 across 5,084 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,095 studies on the registry; 142 are open to participants now.
Of its 535 completed or terminated interventional studies of FDA-regulated products, 356 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition to exclusion criteria under Master Protocol CWMM (NCT06143956)
Have any of the following cardiovascular conditions within 6 months prior to screening:
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive placebo orally
Drug: Placebo
Administered orally
Administered orally
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 32
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 48
Change from Baseline Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)
Time frame: Baseline, Week 32, Week 48
Pharmacokinetics (PK): Area Under the Curve (AUC) of LY4086940 for One Dosing Interval at Steady State
Time frame: Week 48
PK: Maximum Concentration (Cmax) of LY4086940 at Steady State
Time frame: Week 48
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.
Of 141 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 17. This study's planned 14 months is above that.
Counting every sponsor, half of 232 studies reached it within 15 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.